3B Blackbio DX Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹29Cr
- +52.6% YoY
- +52.6% QoQ
- Net profit
- ₹15Cr
- +87.5% YoY
- +36.4% QoQ
- Margin
- 55%
- +14 pp YoY
- −1 pp QoQ
Guidance rank: #34 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
3B Blackbio DX Ltd Q2 FY25 key numbers
- Revenue
- Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. +48.5% YoY).
As stated in 3B Blackbio DX Ltd's Q2 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on 3B Blackbio DX Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. EBITDA for Q2 FY 2024-25: ₹1,929.17 lakh, up from ₹1,059.54 lakh in Q2 FY 2023-24.
From 3B Blackbio DX Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. +48.5% YoY).
- Diagnostic division (3B BlackBio + TRUPCR Europe) Q2 revenue: ₹2,457.55 lakh vs ₹1,465.63 lakh in Q2 FY 2023-24 (approx. +67.6% YoY).
- Export sales (non-COVID) in Q2 FY 2024-25: ₹366.50 lakh vs ₹170.17 lakh in Q2 FY 2023-24 (approx. +115% YoY).
- TRUPCR Europe Ltd. (Manchester site) Q2 sales grew by 51% YoY to ₹404,900 GBP.
- Molecular diagnostic sales for standalone 3B: ₹2,194.18 lakh in Q2 FY 2024-25 vs ₹1,410.19 lakh in Q2 FY 2023-24 (approx. +55.6% YoY).
- Revenue spike from seasonal Flu, Dengue & Chikungunya in Q2 2024-25 contributed extra growth (~28%), expected not to continue in Q3/Q4.
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 40).
- Looking for inorganic growth via acquisition since FY22; will pursue only if it meets internal IRR criteria; may consider share buyback if acquisition candidate not found (Page 40).
- Deployment of some funds planned in joint venture created in Manchester, UK, depending on need (Page 40).
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
3B Blackbio DX Ltd — Quarterly revenue & net profit
3B Blackbio DX Ltd Q2 FY25 results — key figures
| ₹ Cr | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 29 | 19 | +52.6% | 19 | +52.6% |
| Operating profit (EBITDA) | 16 | 8 | +100% | 11 | +45.5% |
| Operating margin | 55% | 41% | +14 pp | 56% | -1 pp |
| Profit before tax | 19 | 10 | +90% | 14 | +35.7% |
| Net profit (PAT) | 15 | 8 | +87.5% | 11 | +36.4% |
| EPS (₹) | 17.07 | 10.46 | +63.2% | 12.97 | +31.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio's management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q2 FY25 results?
Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. EBITDA for Q2 FY 2024-25: ₹1,929.17 lakh, up from ₹1,059.54 lakh in Q2 FY 2023-24.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 40).
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
